Mesoblast Ltd (ASX:MSB) is a leader in providing allogeneic (off the shelf) cellular medicines. It owns a portfolio of late-stage product candidates with three product candidates in Phase 3 trials, being acute graft versus host disease, chronic heart failure and chronic low back pain due to degenerative disc disease. The company has facilities in Melbourne, New York, Singapore and Texas and is listed on the ASX and the NASDAQ.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.51% to 7,819.60.
Here’s today’s latest market update by Drew Meredith, CFP, from Wattle Partners: The S&P/ASX 200 (INDEXASX: XJO) share price is up +0.5% to 7,800.90.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.41% to 7780.
The S&P/ASX 200 (INDEXASX: XJO) Index rose 8.3 points, or 0.1 per cent, to 7,712.5 on Tuesday, while the broader All Ordinaries (INDEXASX: XAO) rose 9.4 points, or 0.1 per cent, to 7,973.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +1.02% to 7,421.20.
Here’s today’s latest updates on the S&P/ASX 200 (INDEXASX: XJO) and the broader All Ordinaries (INDEXASX: XAO) share prices.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.89% to 7,061.60.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished down -0.20% to 7,073.20.
Here’s today’s The Match Out report from Market Matters’ James Gerrish. Key point: the S&P/ASX 200 (INDEXASX: XJO) finished up +0.051% to 7068.80.
